C. Lowry Barnes
Concepts (606)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 57 | 2024 | 289 | 12.450 |
Why?
| | Arthroplasty, Replacement, Hip | 52 | 2024 | 266 | 12.370 |
Why?
| | Antibodies, Neutralizing | 22 | 2025 | 79 | 4.360 |
Why?
| | Allergens | 8 | 2025 | 141 | 2.970 |
Why?
| | Antibodies, Viral | 14 | 2025 | 110 | 2.420 |
Why?
| | Orthopedics | 10 | 2022 | 53 | 2.380 |
Why?
| | Osteoarthritis, Knee | 11 | 2022 | 97 | 2.210 |
Why?
| | Humans | 165 | 2025 | 52114 | 2.080 |
Why?
| | Health Literacy | 5 | 2019 | 131 | 1.980 |
Why?
| | Length of Stay | 18 | 2024 | 666 | 1.940 |
Why?
| | Coronavirus Infections | 9 | 2021 | 188 | 1.840 |
Why?
| | Pneumonia, Viral | 8 | 2020 | 177 | 1.830 |
Why?
| | Fungi | 5 | 2025 | 51 | 1.800 |
Why?
| | Air Pollution, Indoor | 5 | 2025 | 27 | 1.760 |
Why?
| | Reoperation | 13 | 2024 | 463 | 1.750 |
Why?
| | Knee Joint | 19 | 2023 | 165 | 1.750 |
Why?
| | Patient Readmission | 13 | 2024 | 243 | 1.740 |
Why?
| | Aged | 54 | 2024 | 10142 | 1.660 |
Why?
| | Arthroplasty, Replacement | 5 | 2019 | 27 | 1.640 |
Why?
| | Hip Prosthesis | 6 | 2021 | 71 | 1.630 |
Why?
| | Analgesics, Opioid | 10 | 2024 | 587 | 1.630 |
Why?
| | Medicare | 17 | 2024 | 273 | 1.630 |
Why?
| | Preoperative Care | 5 | 2018 | 174 | 1.560 |
Why?
| | Epitopes | 12 | 2025 | 62 | 1.460 |
Why?
| | Retrospective Studies | 43 | 2024 | 6610 | 1.460 |
Why?
| | Hypersensitivity | 6 | 2018 | 81 | 1.370 |
Why?
| | United States | 30 | 2024 | 5168 | 1.360 |
Why?
| | Pandemics | 12 | 2022 | 579 | 1.340 |
Why?
| | Periprosthetic Fractures | 4 | 2022 | 11 | 1.270 |
Why?
| | Postoperative Complications | 13 | 2024 | 1071 | 1.220 |
Why?
| | Pain, Postoperative | 7 | 2024 | 169 | 1.210 |
Why?
| | Prosthesis-Related Infections | 6 | 2023 | 106 | 1.180 |
Why?
| | Range of Motion, Articular | 8 | 2022 | 108 | 1.180 |
Why?
| | Joint Diseases | 3 | 2018 | 39 | 1.160 |
Why?
| | HIV Antibodies | 6 | 2022 | 15 | 1.160 |
Why?
| | HIV-1 | 8 | 2022 | 59 | 1.150 |
Why?
| | Critical Pathways | 3 | 2017 | 36 | 1.130 |
Why?
| | Golf | 3 | 2023 | 9 | 1.130 |
Why?
| | Patient Discharge | 14 | 2022 | 322 | 1.120 |
Why?
| | env Gene Products, Human Immunodeficiency Virus | 5 | 2022 | 5 | 1.120 |
Why?
| | Hip Dislocation | 2 | 2019 | 17 | 1.090 |
Why?
| | Orthopedic Procedures | 6 | 2020 | 71 | 1.080 |
Why?
| | Patient Education as Topic | 5 | 2018 | 318 | 1.050 |
Why?
| | Comprehension | 2 | 2018 | 113 | 1.030 |
Why?
| | Middle Aged | 40 | 2024 | 13028 | 0.990 |
Why?
| | Antibodies, Bispecific | 2 | 2025 | 88 | 0.970 |
Why?
| | Respiratory Tract Diseases | 2 | 2018 | 28 | 0.970 |
Why?
| | Male | 56 | 2024 | 26652 | 0.940 |
Why?
| | HIV Envelope Protein gp120 | 4 | 2020 | 13 | 0.920 |
Why?
| | Prosthesis Failure | 5 | 2020 | 112 | 0.920 |
Why?
| | Climate Change | 2 | 2018 | 53 | 0.920 |
Why?
| | Respiratory Hypersensitivity | 1 | 2025 | 17 | 0.920 |
Why?
| | Immunoglobulin G | 5 | 2021 | 195 | 0.910 |
Why?
| | Antigens, Fungal | 1 | 2025 | 20 | 0.910 |
Why?
| | Female | 55 | 2025 | 28055 | 0.900 |
Why?
| | Osteoarthritis | 6 | 2023 | 60 | 0.870 |
Why?
| | Risk Factors | 18 | 2023 | 3922 | 0.870 |
Why?
| | Pain Management | 3 | 2016 | 175 | 0.870 |
Why?
| | Joint Instability | 2 | 2022 | 43 | 0.870 |
Why?
| | Pollen | 3 | 2018 | 4 | 0.830 |
Why?
| | Hip | 2 | 2020 | 23 | 0.800 |
Why?
| | Anthozoa | 1 | 2022 | 5 | 0.780 |
Why?
| | Cryoelectron Microscopy | 8 | 2025 | 12 | 0.780 |
Why?
| | Diterpenes | 1 | 2022 | 31 | 0.770 |
Why?
| | Polysaccharides | 6 | 2022 | 54 | 0.760 |
Why?
| | Lordosis | 1 | 2022 | 4 | 0.760 |
Why?
| | Opioid-Related Disorders | 5 | 2023 | 399 | 0.760 |
Why?
| | Prosthesis Design | 4 | 2021 | 260 | 0.760 |
Why?
| | Kyphosis | 1 | 2022 | 16 | 0.750 |
Why?
| | Hospitals | 10 | 2024 | 180 | 0.750 |
Why?
| | HIV Infections | 6 | 2022 | 382 | 0.740 |
Why?
| | Housing | 4 | 2016 | 48 | 0.740 |
Why?
| | Knee | 3 | 2021 | 25 | 0.740 |
Why?
| | Animals | 27 | 2025 | 13332 | 0.700 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 249 | 0.700 |
Why?
| | Blood Transfusion | 3 | 2016 | 129 | 0.690 |
Why?
| | Transurethral Resection of Prostate | 1 | 2021 | 10 | 0.690 |
Why?
| | Prostatic Hyperplasia | 1 | 2021 | 37 | 0.680 |
Why?
| | Dust | 3 | 2019 | 23 | 0.670 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2020 | 19 | 0.660 |
Why?
| | Knee Prosthesis | 4 | 2023 | 52 | 0.660 |
Why?
| | Antibodies, Monoclonal | 12 | 2025 | 475 | 0.630 |
Why?
| | Asthma | 4 | 2017 | 314 | 0.620 |
Why?
| | Aged, 80 and over | 13 | 2024 | 3382 | 0.620 |
Why?
| | Disease Susceptibility | 1 | 2019 | 96 | 0.620 |
Why?
| | Anesthesia, General | 4 | 2024 | 97 | 0.610 |
Why?
| | Environment | 1 | 2019 | 88 | 0.610 |
Why?
| | Surgery Department, Hospital | 1 | 2019 | 4 | 0.600 |
Why?
| | Bone Cements | 1 | 2019 | 30 | 0.600 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 26 | 0.600 |
Why?
| | Societies, Medical | 2 | 2020 | 200 | 0.590 |
Why?
| | Hip Joint | 2 | 2020 | 56 | 0.590 |
Why?
| | Diabetic Foot | 1 | 2019 | 76 | 0.580 |
Why?
| | Food Hypersensitivity | 1 | 2019 | 100 | 0.580 |
Why?
| | Cost Savings | 2 | 2017 | 58 | 0.570 |
Why?
| | Models, Molecular | 9 | 2021 | 351 | 0.570 |
Why?
| | Comorbidity | 5 | 2018 | 628 | 0.570 |
Why?
| | Arthroplasty | 4 | 2023 | 27 | 0.560 |
Why?
| | Yoga | 1 | 2018 | 14 | 0.560 |
Why?
| | Environmental Exposure | 5 | 2025 | 214 | 0.540 |
Why?
| | Hospitals, Teaching | 2 | 2019 | 52 | 0.540 |
Why?
| | Protein Binding | 9 | 2024 | 665 | 0.530 |
Why?
| | Inpatients | 7 | 2020 | 206 | 0.530 |
Why?
| | Clinical Protocols | 1 | 2017 | 106 | 0.530 |
Why?
| | Postoperative Period | 6 | 2018 | 170 | 0.520 |
Why?
| | Quadriceps Muscle | 4 | 2022 | 47 | 0.510 |
Why?
| | Arthritis, Infectious | 3 | 2023 | 43 | 0.510 |
Why?
| | AIDS Vaccines | 3 | 2021 | 11 | 0.510 |
Why?
| | Patient Navigation | 1 | 2016 | 13 | 0.510 |
Why?
| | B-Lymphocytes | 7 | 2024 | 180 | 0.510 |
Why?
| | Antifibrinolytic Agents | 1 | 2016 | 16 | 0.500 |
Why?
| | Binding Sites | 6 | 2024 | 375 | 0.500 |
Why?
| | Tranexamic Acid | 1 | 2016 | 15 | 0.500 |
Why?
| | Anti-Bacterial Agents | 4 | 2023 | 796 | 0.490 |
Why?
| | Early Ambulation | 1 | 2016 | 5 | 0.490 |
Why?
| | Musculoskeletal Pain | 1 | 2016 | 7 | 0.490 |
Why?
| | Caregivers | 1 | 2018 | 236 | 0.480 |
Why?
| | Immunity, Innate | 1 | 2016 | 112 | 0.470 |
Why?
| | Publishing | 1 | 2016 | 40 | 0.470 |
Why?
| | Quality of Health Care | 1 | 2017 | 187 | 0.470 |
Why?
| | Periodicals as Topic | 1 | 2016 | 62 | 0.460 |
Why?
| | Analgesia, Epidural | 1 | 2015 | 28 | 0.450 |
Why?
| | Bupivacaine | 1 | 2015 | 29 | 0.440 |
Why?
| | Adult | 24 | 2024 | 14095 | 0.440 |
Why?
| | Narcotics | 3 | 2020 | 108 | 0.430 |
Why?
| | Intermittent Pneumatic Compression Devices | 1 | 2014 | 2 | 0.430 |
Why?
| | Air Pollutants | 2 | 2013 | 72 | 0.420 |
Why?
| | Epilepsy | 1 | 2016 | 184 | 0.420 |
Why?
| | Treatment Outcome | 10 | 2024 | 5456 | 0.420 |
Why?
| | Exercise | 1 | 2018 | 552 | 0.410 |
Why?
| | Venous Thromboembolism | 1 | 2014 | 75 | 0.390 |
Why?
| | Cross Reactions | 3 | 2021 | 41 | 0.390 |
Why?
| | DNA Methylation | 1 | 2016 | 583 | 0.380 |
Why?
| | Mutation | 7 | 2021 | 1318 | 0.370 |
Why?
| | Activities of Daily Living | 3 | 2023 | 182 | 0.370 |
Why?
| | Health Expenditures | 3 | 2017 | 74 | 0.370 |
Why?
| | Work Schedule Tolerance | 2 | 2021 | 5 | 0.360 |
Why?
| | Sleep Disorders, Circadian Rhythm | 2 | 2021 | 5 | 0.360 |
Why?
| | Mice | 13 | 2025 | 5877 | 0.360 |
Why?
| | Osteonecrosis | 2 | 2022 | 35 | 0.360 |
Why?
| | Receptors, Virus | 2 | 2021 | 25 | 0.350 |
Why?
| | Lower Extremity | 3 | 2023 | 97 | 0.330 |
Why?
| | Crystallography, X-Ray | 4 | 2021 | 156 | 0.320 |
Why?
| | Pain | 4 | 2024 | 353 | 0.320 |
Why?
| | Cross-Sectional Studies | 6 | 2018 | 1665 | 0.320 |
Why?
| | Odds Ratio | 5 | 2019 | 564 | 0.320 |
Why?
| | Acetabulum | 3 | 2020 | 38 | 0.320 |
Why?
| | Neutralization Tests | 7 | 2023 | 26 | 0.320 |
Why?
| | Young Adult | 10 | 2021 | 4307 | 0.310 |
Why?
| | Tibial Fractures | 2 | 2021 | 33 | 0.300 |
Why?
| | Cost-Benefit Analysis | 3 | 2021 | 267 | 0.300 |
Why?
| | Osteoarthritis, Hip | 3 | 2019 | 28 | 0.300 |
Why?
| | Fee-for-Service Plans | 2 | 2020 | 18 | 0.290 |
Why?
| | Nanoparticles | 3 | 2021 | 127 | 0.280 |
Why?
| | Movement | 4 | 2021 | 81 | 0.280 |
Why?
| | Crystallization | 3 | 2016 | 33 | 0.270 |
Why?
| | Patient Satisfaction | 2 | 2020 | 283 | 0.270 |
Why?
| | Viscosupplements | 2 | 2017 | 14 | 0.270 |
Why?
| | Hyaluronic Acid | 2 | 2017 | 38 | 0.260 |
Why?
| | Antibody Affinity | 3 | 2021 | 9 | 0.260 |
Why?
| | Mice, Inbred BALB C | 2 | 2025 | 307 | 0.260 |
Why?
| | Adolescent | 10 | 2021 | 6681 | 0.250 |
Why?
| | Recombinant Proteins | 2 | 2020 | 492 | 0.250 |
Why?
| | Indians, North American | 2 | 2018 | 36 | 0.250 |
Why?
| | Risk | 2 | 2017 | 312 | 0.240 |
Why?
| | HEK293 Cells | 4 | 2020 | 231 | 0.240 |
Why?
| | Smoking | 3 | 2018 | 516 | 0.240 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2016 | 69 | 0.230 |
Why?
| | Logistic Models | 3 | 2016 | 925 | 0.230 |
Why?
| | Spores, Fungal | 1 | 2025 | 20 | 0.230 |
Why?
| | Muscle Strength | 3 | 2022 | 131 | 0.230 |
Why?
| | Symbiosis | 1 | 2024 | 12 | 0.230 |
Why?
| | Staphylococcus epidermidis | 1 | 2024 | 17 | 0.220 |
Why?
| | Reproducibility of Results | 4 | 2022 | 1214 | 0.220 |
Why?
| | Antibodies, Bacterial | 1 | 2024 | 30 | 0.220 |
Why?
| | RNA Polymerase II | 1 | 2024 | 14 | 0.220 |
Why?
| | Magnesium | 1 | 2024 | 32 | 0.220 |
Why?
| | Catalytic Domain | 1 | 2024 | 60 | 0.220 |
Why?
| | Hip Fractures | 2 | 2023 | 47 | 0.220 |
Why?
| | Molecular Dynamics Simulation | 1 | 2024 | 44 | 0.220 |
Why?
| | Poverty | 2 | 2016 | 220 | 0.220 |
Why?
| | Arthralgia | 3 | 2022 | 44 | 0.220 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 71 | 0.220 |
Why?
| | Cricetulus | 3 | 2020 | 100 | 0.220 |
Why?
| | CHO Cells | 3 | 2020 | 123 | 0.210 |
Why?
| | Delivery of Health Care | 2 | 2017 | 318 | 0.210 |
Why?
| | Protein Multimerization | 3 | 2021 | 57 | 0.210 |
Why?
| | Public Opinion | 2 | 2021 | 21 | 0.210 |
Why?
| | Meteorological Concepts | 1 | 2003 | 2 | 0.210 |
Why?
| | Spores | 1 | 2003 | 2 | 0.210 |
Why?
| | Hospital Mortality | 2 | 2016 | 451 | 0.210 |
Why?
| | Information Services | 1 | 2003 | 13 | 0.210 |
Why?
| | Femur | 2 | 2021 | 132 | 0.210 |
Why?
| | Antibiotic Prophylaxis | 1 | 2023 | 61 | 0.200 |
Why?
| | Host-Pathogen Interactions | 2 | 2021 | 131 | 0.200 |
Why?
| | Knee Injuries | 1 | 2023 | 28 | 0.200 |
Why?
| | Transcription, Genetic | 1 | 2024 | 373 | 0.200 |
Why?
| | Caribbean Region | 1 | 2022 | 5 | 0.200 |
Why?
| | Femoral Fractures | 1 | 2023 | 40 | 0.200 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 42 | 0.190 |
Why?
| | Macaca mulatta | 2 | 2020 | 93 | 0.190 |
Why?
| | Bone Neoplasms | 1 | 2024 | 184 | 0.190 |
Why?
| | Braces | 1 | 2002 | 9 | 0.190 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 78 | 0.190 |
Why?
| | Proteins | 2 | 2016 | 347 | 0.190 |
Why?
| | Gait | 2 | 2021 | 88 | 0.190 |
Why?
| | Myositis | 1 | 2022 | 20 | 0.190 |
Why?
| | Outpatients | 2 | 2020 | 125 | 0.180 |
Why?
| | Pain Measurement | 3 | 2019 | 256 | 0.180 |
Why?
| | Pelvis | 1 | 2022 | 66 | 0.180 |
Why?
| | Sepsis | 2 | 2021 | 229 | 0.180 |
Why?
| | Molecular Structure | 1 | 2022 | 315 | 0.180 |
Why?
| | Osteocytes | 1 | 2024 | 225 | 0.180 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 21 | 0.180 |
Why?
| | Critical Illness | 2 | 2021 | 310 | 0.180 |
Why?
| | Cricetinae | 2 | 2020 | 189 | 0.180 |
Why?
| | Injections, Intra-Articular | 3 | 2017 | 38 | 0.180 |
Why?
| | Skin | 1 | 2024 | 418 | 0.180 |
Why?
| | Databases, Factual | 4 | 2019 | 714 | 0.180 |
Why?
| | Metal-on-Metal Joint Prostheses | 1 | 2021 | 5 | 0.180 |
Why?
| | Cost of Illness | 1 | 2022 | 120 | 0.180 |
Why?
| | Multiple Myeloma | 1 | 2016 | 2999 | 0.180 |
Why?
| | Anemia, Sickle Cell | 1 | 2022 | 101 | 0.180 |
Why?
| | Lumbar Vertebrae | 1 | 2022 | 100 | 0.180 |
Why?
| | Glycosylation | 2 | 2019 | 103 | 0.180 |
Why?
| | Radiography | 5 | 2019 | 472 | 0.170 |
Why?
| | Protein Engineering | 2 | 2020 | 18 | 0.170 |
Why?
| | Vaccines, Synthetic | 1 | 2021 | 21 | 0.170 |
Why?
| | Crowdsourcing | 1 | 2021 | 10 | 0.170 |
Why?
| | Immunity, Humoral | 1 | 2021 | 23 | 0.170 |
Why?
| | Molecular Biology | 1 | 2021 | 27 | 0.170 |
Why?
| | Posture | 1 | 2021 | 66 | 0.170 |
Why?
| | Vaccination | 2 | 2022 | 296 | 0.170 |
Why?
| | Joints | 2 | 2018 | 19 | 0.170 |
Why?
| | Femur Head Necrosis | 1 | 2020 | 17 | 0.170 |
Why?
| | Intubation, Intratracheal | 1 | 2021 | 117 | 0.170 |
Why?
| | Protein Conformation | 4 | 2024 | 177 | 0.170 |
Why?
| | Decompression, Surgical | 1 | 2020 | 49 | 0.170 |
Why?
| | Epitope Mapping | 1 | 2020 | 6 | 0.170 |
Why?
| | Dissociative Disorders | 1 | 2020 | 8 | 0.170 |
Why?
| | Hydrocortisone | 1 | 2021 | 113 | 0.170 |
Why?
| | Immunization, Passive | 1 | 2020 | 28 | 0.170 |
Why?
| | Adrenal Cortex Hormones | 2 | 2020 | 114 | 0.170 |
Why?
| | Polyethylene | 1 | 2020 | 18 | 0.170 |
Why?
| | Politics | 1 | 2020 | 28 | 0.170 |
Why?
| | Bariatric Surgery | 1 | 2021 | 44 | 0.160 |
Why?
| | Diagnosis-Related Groups | 2 | 2017 | 18 | 0.160 |
Why?
| | Obesity, Morbid | 1 | 2021 | 89 | 0.160 |
Why?
| | Peptide Fragments | 1 | 2020 | 207 | 0.160 |
Why?
| | Leadership | 1 | 2020 | 104 | 0.160 |
Why?
| | Foot Orthoses | 1 | 2019 | 7 | 0.160 |
Why?
| | External Fixators | 1 | 2019 | 10 | 0.160 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2021 | 146 | 0.150 |
Why?
| | Costs and Cost Analysis | 2 | 2017 | 95 | 0.150 |
Why?
| | Viral Proteins | 1 | 2021 | 164 | 0.150 |
Why?
| | Clone Cells | 1 | 2019 | 76 | 0.150 |
Why?
| | Fracture Healing | 2 | 1996 | 27 | 0.150 |
Why?
| | Tobramycin | 1 | 2019 | 16 | 0.150 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 100 | 0.150 |
Why?
| | Antiviral Agents | 1 | 2020 | 177 | 0.150 |
Why?
| | After-Hours Care | 1 | 2019 | 12 | 0.150 |
Why?
| | Models, Neurological | 1 | 2019 | 50 | 0.150 |
Why?
| | Systems Biology | 1 | 2019 | 33 | 0.150 |
Why?
| | Prostheses and Implants | 1 | 2019 | 54 | 0.150 |
Why?
| | HIV Envelope Protein gp41 | 1 | 2018 | 5 | 0.150 |
Why?
| | Maternal Exposure | 1 | 2019 | 101 | 0.150 |
Why?
| | Bayes Theorem | 1 | 2019 | 120 | 0.150 |
Why?
| | Hospitals, University | 1 | 2019 | 74 | 0.150 |
Why?
| | Postural Balance | 2 | 2021 | 59 | 0.150 |
Why?
| | Gardening | 1 | 2018 | 2 | 0.150 |
Why?
| | Virus Internalization | 1 | 2018 | 20 | 0.150 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2019 | 52 | 0.140 |
Why?
| | Rural Population | 1 | 2023 | 571 | 0.140 |
Why?
| | Vancomycin | 1 | 2019 | 86 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2022 | 296 | 0.140 |
Why?
| | Plants | 1 | 2018 | 31 | 0.140 |
Why?
| | Immunoglobulin A | 3 | 2024 | 46 | 0.140 |
Why?
| | Exercise Test | 1 | 2019 | 142 | 0.140 |
Why?
| | Sulfhydryl Compounds | 1 | 2018 | 17 | 0.140 |
Why?
| | Radioisotopes | 1 | 2018 | 17 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2019 | 71 | 0.140 |
Why?
| | Medicaid | 2 | 2022 | 263 | 0.140 |
Why?
| | Recreation | 1 | 2018 | 21 | 0.140 |
Why?
| | Rotation | 1 | 2018 | 44 | 0.140 |
Why?
| | Arsenic | 1 | 2018 | 22 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2019 | 104 | 0.140 |
Why?
| | Infant, Premature | 1 | 2021 | 327 | 0.140 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 270 | 0.140 |
Why?
| | Cell Line | 1 | 2020 | 1018 | 0.140 |
Why?
| | Smoke-Free Policy | 1 | 2018 | 15 | 0.140 |
Why?
| | Benzodiazepines | 1 | 2018 | 71 | 0.140 |
Why?
| | Tramadol | 1 | 2018 | 30 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2018 | 111 | 0.140 |
Why?
| | Child, Preschool | 6 | 2016 | 4001 | 0.140 |
Why?
| | Breast Feeding | 1 | 2019 | 195 | 0.140 |
Why?
| | Child | 8 | 2020 | 7147 | 0.130 |
Why?
| | Incidence | 3 | 2019 | 1070 | 0.130 |
Why?
| | Body Mass Index | 2 | 2018 | 699 | 0.130 |
Why?
| | Subacute Care | 1 | 2017 | 5 | 0.130 |
Why?
| | Risk Assessment | 2 | 2019 | 1339 | 0.130 |
Why?
| | Recovery of Function | 1 | 2018 | 201 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2018 | 147 | 0.130 |
Why?
| | Neurotransmitter Agents | 1 | 2017 | 33 | 0.130 |
Why?
| | Early Medical Intervention | 1 | 2017 | 14 | 0.130 |
Why?
| | Optical Imaging | 1 | 2017 | 25 | 0.130 |
Why?
| | Kansas | 1 | 2016 | 8 | 0.130 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 29 | 0.130 |
Why?
| | Language | 1 | 2018 | 136 | 0.130 |
Why?
| | Reimbursement Mechanisms | 1 | 2017 | 24 | 0.130 |
Why?
| | Immunologic Memory | 3 | 2021 | 32 | 0.130 |
Why?
| | Dietary Proteins | 1 | 2019 | 252 | 0.130 |
Why?
| | Patient Safety | 1 | 2017 | 102 | 0.130 |
Why?
| | Nut Hypersensitivity | 1 | 2016 | 3 | 0.130 |
Why?
| | Fractures, Bone | 4 | 1992 | 104 | 0.130 |
Why?
| | Cocos | 1 | 2016 | 3 | 0.130 |
Why?
| | Fractures, Open | 1 | 1996 | 8 | 0.130 |
Why?
| | Football | 1 | 2018 | 75 | 0.130 |
Why?
| | Fluorescent Dyes | 1 | 2017 | 90 | 0.130 |
Why?
| | Time Factors | 5 | 2021 | 2970 | 0.130 |
Why?
| | Nuts | 1 | 2016 | 8 | 0.130 |
Why?
| | Zinc | 1 | 2017 | 56 | 0.130 |
Why?
| | Hospitals, Community | 1 | 2016 | 19 | 0.120 |
Why?
| | Glutamic Acid | 1 | 2017 | 104 | 0.120 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 136 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 234 | 0.120 |
Why?
| | Social Class | 1 | 2016 | 95 | 0.120 |
Why?
| | Social Support | 1 | 2018 | 268 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2018 | 297 | 0.120 |
Why?
| | Quality Improvement | 1 | 2018 | 223 | 0.120 |
Why?
| | Anesthesia, Spinal | 1 | 2016 | 17 | 0.120 |
Why?
| | Peer Review, Research | 1 | 2016 | 14 | 0.120 |
Why?
| | Anesthesia, Conduction | 1 | 2016 | 15 | 0.120 |
Why?
| | Breast Neoplasms | 1 | 2024 | 1199 | 0.120 |
Why?
| | Anemia | 1 | 2016 | 75 | 0.120 |
Why?
| | Congresses as Topic | 1 | 2016 | 48 | 0.120 |
Why?
| | Hyperalgesia | 1 | 2016 | 39 | 0.120 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 58 | 0.120 |
Why?
| | Prescription Drug Misuse | 1 | 2016 | 33 | 0.120 |
Why?
| | Hemoglobins | 1 | 2016 | 111 | 0.120 |
Why?
| | Chronic Disease | 1 | 2018 | 585 | 0.120 |
Why?
| | Pneumonia | 1 | 2016 | 123 | 0.120 |
Why?
| | Ambulatory Care Facilities | 1 | 2016 | 124 | 0.120 |
Why?
| | Environmental Health | 1 | 2015 | 14 | 0.110 |
Why?
| | Injections, Epidural | 1 | 2015 | 10 | 0.110 |
Why?
| | Liposomes | 1 | 2015 | 53 | 0.110 |
Why?
| | Arthroplasty, Replacement, Ankle | 1 | 2014 | 3 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2016 | 600 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 123 | 0.110 |
Why?
| | Cohort Studies | 4 | 2021 | 1541 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2020 | 2282 | 0.110 |
Why?
| | Age Factors | 1 | 2017 | 1125 | 0.110 |
Why?
| | Anesthetics, Local | 1 | 2015 | 77 | 0.110 |
Why?
| | Phylogeny | 3 | 2021 | 229 | 0.100 |
Why?
| | Bacteria | 1 | 2015 | 220 | 0.100 |
Why?
| | Drug Overdose | 1 | 2016 | 163 | 0.100 |
Why?
| | Socioeconomic Factors | 3 | 2023 | 603 | 0.100 |
Why?
| | Kinetics | 3 | 2021 | 616 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2017 | 316 | 0.100 |
Why?
| | Arthropod Proteins | 1 | 2013 | 2 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2016 | 1035 | 0.100 |
Why?
| | Antigens, Dermatophagoides | 1 | 2013 | 4 | 0.100 |
Why?
| | Humeral Fractures | 1 | 1992 | 8 | 0.100 |
Why?
| | Cysteine Endopeptidases | 1 | 2013 | 63 | 0.100 |
Why?
| | Joint Prosthesis | 1 | 1992 | 12 | 0.100 |
Why?
| | Pulmonary Embolism | 1 | 2014 | 83 | 0.100 |
Why?
| | Venous Thrombosis | 1 | 2014 | 90 | 0.100 |
Why?
| | Patient Positioning | 1 | 2013 | 31 | 0.100 |
Why?
| | Mass Screening | 1 | 2016 | 356 | 0.100 |
Why?
| | Environmental Monitoring | 1 | 2013 | 74 | 0.100 |
Why?
| | Carpal Bones | 1 | 1992 | 2 | 0.100 |
Why?
| | Synostosis | 1 | 1992 | 2 | 0.100 |
Why?
| | Shoulder Joint | 1 | 1992 | 38 | 0.100 |
Why?
| | Glycoproteins | 1 | 2013 | 122 | 0.100 |
Why?
| | Diseases in Twins | 1 | 1992 | 14 | 0.100 |
Why?
| | Health Promotion | 1 | 2015 | 270 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2014 | 239 | 0.090 |
Why?
| | Fungal Proteins | 1 | 2013 | 114 | 0.090 |
Why?
| | Tibia | 2 | 2023 | 112 | 0.090 |
Why?
| | Arm Injuries | 1 | 1991 | 10 | 0.090 |
Why?
| | Acute Kidney Injury | 1 | 2016 | 384 | 0.090 |
Why?
| | Aging | 1 | 1996 | 701 | 0.090 |
Why?
| | Lidocaine | 1 | 1991 | 46 | 0.090 |
Why?
| | Immune Evasion | 2 | 2021 | 15 | 0.090 |
Why?
| | Immunoglobulin E | 2 | 2016 | 92 | 0.090 |
Why?
| | Epitopes, B-Lymphocyte | 2 | 2021 | 4 | 0.090 |
Why?
| | Stroke | 1 | 2016 | 514 | 0.090 |
Why?
| | Nerve Block | 1 | 1991 | 42 | 0.090 |
Why?
| | Immunization | 2 | 2021 | 68 | 0.090 |
Why?
| | Antigens, Viral | 2 | 2021 | 43 | 0.090 |
Why?
| | Electrons | 2 | 2024 | 20 | 0.090 |
Why?
| | Mental Disorders | 1 | 2016 | 426 | 0.090 |
Why?
| | Brain | 1 | 2019 | 1311 | 0.090 |
Why?
| | Osteoclasts | 2 | 2024 | 427 | 0.090 |
Why?
| | Lasers | 2 | 2024 | 65 | 0.090 |
Why?
| | Fatigue | 2 | 2021 | 129 | 0.080 |
Why?
| | Immunoglobulin M | 2 | 2021 | 60 | 0.080 |
Why?
| | Viral Vaccines | 2 | 2021 | 16 | 0.080 |
Why?
| | Antigen-Antibody Complex | 2 | 2021 | 35 | 0.080 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 2 | 2021 | 6 | 0.080 |
Why?
| | Sleep | 2 | 2021 | 185 | 0.080 |
Why?
| | Antibody Specificity | 2 | 2020 | 36 | 0.080 |
Why?
| | Signal Transduction | 1 | 2017 | 1699 | 0.080 |
Why?
| | Obesity | 1 | 2017 | 1183 | 0.070 |
Why?
| | Molecular Conformation | 2 | 2018 | 69 | 0.070 |
Why?
| | Amino Acid Sequence | 2 | 2019 | 566 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1101 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 1872 | 0.070 |
Why?
| | Muscle, Skeletal | 2 | 2022 | 808 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 157 | 0.060 |
Why?
| | Quality of Life | 2 | 2022 | 878 | 0.060 |
Why?
| | Inflammation | 2 | 2022 | 641 | 0.060 |
Why?
| | Air | 1 | 2005 | 23 | 0.060 |
Why?
| | Hospitalization | 2 | 2020 | 739 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 494 | 0.060 |
Why?
| | Polyethylenes | 2 | 2023 | 14 | 0.060 |
Why?
| | Tetanus Toxin | 1 | 2024 | 1 | 0.060 |
Why?
| | Antibody Formation | 1 | 2024 | 51 | 0.060 |
Why?
| | Prospective Payment System | 1 | 2024 | 5 | 0.050 |
Why?
| | 5-Methoxytryptamine | 1 | 1994 | 1 | 0.050 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1994 | 7 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 1994 | 23 | 0.050 |
Why?
| | Blastocyst | 1 | 1994 | 15 | 0.050 |
Why?
| | Abnormalities, Drug-Induced | 1 | 1994 | 18 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 128 | 0.050 |
Why?
| | Melatonin | 1 | 1994 | 17 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2024 | 208 | 0.050 |
Why?
| | Fetal Diseases | 1 | 1994 | 63 | 0.050 |
Why?
| | Health Status | 1 | 2005 | 300 | 0.050 |
Why?
| | Quality Indicators, Health Care | 1 | 2024 | 91 | 0.050 |
Why?
| | Particle Size | 1 | 2003 | 78 | 0.050 |
Why?
| | Algorithms | 2 | 2019 | 663 | 0.050 |
Why?
| | Arkansas | 2 | 2019 | 2016 | 0.050 |
Why?
| | International Classification of Diseases | 1 | 2023 | 67 | 0.050 |
Why?
| | Aerosols | 1 | 2003 | 75 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 83 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 246 | 0.050 |
Why?
| | Germ Cells | 1 | 2022 | 14 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2023 | 149 | 0.050 |
Why?
| | Ion Channels | 1 | 2023 | 70 | 0.050 |
Why?
| | Administration, Oral | 1 | 2023 | 453 | 0.050 |
Why?
| | Health Status Indicators | 1 | 2002 | 80 | 0.050 |
Why?
| | Antibodies, Heterophile | 1 | 2021 | 1 | 0.050 |
Why?
| | Transcriptome | 1 | 2024 | 363 | 0.050 |
Why?
| | Macaca | 1 | 2021 | 9 | 0.050 |
Why?
| | Benchmarking | 1 | 2022 | 64 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2024 | 337 | 0.050 |
Why?
| | Muscles | 1 | 2022 | 108 | 0.040 |
Why?
| | New York | 1 | 2021 | 49 | 0.040 |
Why?
| | Chromium | 1 | 2021 | 4 | 0.040 |
Why?
| | Femur Neck | 1 | 2021 | 6 | 0.040 |
Why?
| | Leg | 1 | 2022 | 121 | 0.040 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2021 | 21 | 0.040 |
Why?
| | Cobalt | 1 | 2021 | 17 | 0.040 |
Why?
| | Antigen-Antibody Reactions | 1 | 2021 | 14 | 0.040 |
Why?
| | Back | 1 | 2021 | 5 | 0.040 |
Why?
| | Protein Structure, Quaternary | 1 | 2021 | 26 | 0.040 |
Why?
| | Immunoglobulin Variable Region | 1 | 2021 | 17 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 197 | 0.040 |
Why?
| | Torso | 1 | 2021 | 15 | 0.040 |
Why?
| | Fracture Fixation, Internal | 1 | 2021 | 42 | 0.040 |
Why?
| | Immune Sera | 1 | 2021 | 15 | 0.040 |
Why?
| | Indoles | 1 | 1994 | 276 | 0.040 |
Why?
| | HLA Antigens | 1 | 2021 | 53 | 0.040 |
Why?
| | APACHE | 1 | 2021 | 25 | 0.040 |
Why?
| | Organ Dysfunction Scores | 1 | 2021 | 20 | 0.040 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2021 | 7 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 16 | 0.040 |
Why?
| | Genome, Viral | 1 | 2021 | 80 | 0.040 |
Why?
| | Directed Molecular Evolution | 1 | 2020 | 2 | 0.040 |
Why?
| | Intestinal Perforation | 1 | 2021 | 24 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2021 | 24 | 0.040 |
Why?
| | Workplace | 1 | 2021 | 94 | 0.040 |
Why?
| | Databases, Protein | 1 | 2021 | 28 | 0.040 |
Why?
| | Government | 1 | 2020 | 3 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 109 | 0.040 |
Why?
| | Virulence | 1 | 2021 | 160 | 0.040 |
Why?
| | Public Health | 1 | 2003 | 222 | 0.040 |
Why?
| | Bone Transplantation | 1 | 2020 | 42 | 0.040 |
Why?
| | Femur Head | 1 | 2020 | 26 | 0.040 |
Why?
| | Psychological Theory | 1 | 2020 | 26 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 1418 | 0.040 |
Why?
| | Cefazolin | 1 | 2020 | 11 | 0.040 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2021 | 40 | 0.040 |
Why?
| | North America | 1 | 2020 | 75 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 96 | 0.040 |
Why?
| | Penicillins | 1 | 2020 | 28 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2022 | 281 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2021 | 77 | 0.040 |
Why?
| | Dependovirus | 1 | 2021 | 103 | 0.040 |
Why?
| | Salvage Therapy | 1 | 2021 | 136 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 404 | 0.040 |
Why?
| | Operating Rooms | 1 | 2020 | 27 | 0.040 |
Why?
| | Osteoblasts | 1 | 2023 | 473 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 70 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 46 | 0.040 |
Why?
| | Patella | 1 | 2019 | 11 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2020 | 90 | 0.040 |
Why?
| | Intestines | 1 | 2021 | 154 | 0.040 |
Why?
| | Heel | 1 | 2019 | 6 | 0.040 |
Why?
| | Shoes | 1 | 2019 | 14 | 0.040 |
Why?
| | Sutures | 1 | 2019 | 36 | 0.040 |
Why?
| | Cross-Priming | 1 | 2019 | 2 | 0.040 |
Why?
| | Virus Replication | 1 | 2021 | 150 | 0.040 |
Why?
| | Immunodominant Epitopes | 1 | 2019 | 9 | 0.040 |
Why?
| | Bone and Bones | 1 | 2023 | 492 | 0.040 |
Why?
| | Software | 1 | 2021 | 280 | 0.040 |
Why?
| | Time and Motion Studies | 1 | 2019 | 11 | 0.040 |
Why?
| | Gestational Age | 1 | 2021 | 418 | 0.040 |
Why?
| | Sports Equipment | 1 | 2019 | 4 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2019 | 92 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 209 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2019 | 180 | 0.040 |
Why?
| | Physical Examination | 1 | 2019 | 98 | 0.040 |
Why?
| | Body Weight | 1 | 2021 | 526 | 0.040 |
Why?
| | Telephone | 1 | 2019 | 70 | 0.040 |
Why?
| | Sequence Analysis, Protein | 1 | 2018 | 19 | 0.040 |
Why?
| | Biopsy | 1 | 2021 | 599 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 160 | 0.040 |
Why?
| | Pollination | 1 | 2018 | 2 | 0.040 |
Why?
| | Sequence Alignment | 1 | 2018 | 120 | 0.040 |
Why?
| | Rabbits | 1 | 2019 | 371 | 0.040 |
Why?
| | Radiochemistry | 1 | 2018 | 2 | 0.040 |
Why?
| | Bombesin | 1 | 2018 | 2 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2019 | 147 | 0.040 |
Why?
| | Electronic Health Records | 1 | 2021 | 267 | 0.040 |
Why?
| | Drug Stability | 1 | 2018 | 38 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2019 | 127 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2020 | 288 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2018 | 172 | 0.030 |
Why?
| | Isotope Labeling | 1 | 2018 | 58 | 0.030 |
Why?
| | Prospective Studies | 2 | 2002 | 2424 | 0.030 |
Why?
| | Morphine | 1 | 2018 | 103 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 290 | 0.030 |
Why?
| | Molecular Weight | 1 | 2017 | 77 | 0.030 |
Why?
| | Ultracentrifugation | 1 | 2017 | 10 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2017 | 19 | 0.030 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2017 | 17 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 59 | 0.030 |
Why?
| | Universities | 1 | 2018 | 172 | 0.030 |
Why?
| | Protein Folding | 1 | 2017 | 60 | 0.030 |
Why?
| | Macadamia | 1 | 2016 | 1 | 0.030 |
Why?
| | Solubility | 1 | 2017 | 81 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 124 | 0.030 |
Why?
| | Attitude to Health | 1 | 2018 | 191 | 0.030 |
Why?
| | Oxygen | 1 | 2019 | 333 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2017 | 112 | 0.030 |
Why?
| | Humidity | 1 | 2016 | 4 | 0.030 |
Why?
| | Volatilization | 1 | 2016 | 5 | 0.030 |
Why?
| | Diffusion | 1 | 2016 | 11 | 0.030 |
Why?
| | Probability | 1 | 2016 | 171 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2021 | 1467 | 0.030 |
Why?
| | Protein Array Analysis | 1 | 2015 | 24 | 0.030 |
Why?
| | Genes, Bacterial | 1 | 2015 | 51 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2019 | 1193 | 0.030 |
Why?
| | Students | 1 | 2018 | 227 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 115 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2019 | 1017 | 0.030 |
Why?
| | Hazardous Substances | 1 | 2015 | 17 | 0.030 |
Why?
| | Temperature | 1 | 2016 | 164 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 515 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 290 | 0.030 |
Why?
| | Corrosion | 1 | 2014 | 4 | 0.030 |
Why?
| | Safety | 1 | 2015 | 80 | 0.030 |
Why?
| | Urban Population | 1 | 2015 | 161 | 0.030 |
Why?
| | Data Collection | 1 | 2016 | 286 | 0.030 |
Why?
| | Ions | 1 | 2014 | 32 | 0.030 |
Why?
| | Sf9 Cells | 1 | 2014 | 2 | 0.030 |
Why?
| | Metals | 1 | 2014 | 37 | 0.030 |
Why?
| | Disease Progression | 1 | 2017 | 866 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2017 | 315 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2021 | 2859 | 0.030 |
Why?
| | Escherichia coli | 1 | 2014 | 181 | 0.030 |
Why?
| | Health Personnel | 1 | 2016 | 251 | 0.030 |
Why?
| | Twins, Monozygotic | 1 | 1992 | 16 | 0.020 |
Why?
| | Thrombophlebitis | 1 | 1992 | 18 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1992 | 116 | 0.020 |
Why?
| | Vena Cava Filters | 1 | 1992 | 30 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1991 | 133 | 0.020 |
Why?
| | Prognosis | 1 | 1996 | 2093 | 0.020 |
Why?
| | Pelvic Bones | 1 | 1990 | 13 | 0.020 |
Why?
| | Dextrans | 1 | 1990 | 16 | 0.020 |
Why?
| | Thromboembolism | 1 | 1990 | 49 | 0.020 |
Why?
| | Leg Injuries | 1 | 1989 | 10 | 0.020 |
Why?
| | Irritants | 1 | 2008 | 1 | 0.020 |
Why?
| | Ergosterol | 1 | 2008 | 10 | 0.020 |
Why?
| | Mycotoxins | 1 | 2008 | 11 | 0.020 |
Why?
| | Glucans | 1 | 2008 | 10 | 0.020 |
Why?
| | Surgical Flaps | 1 | 1989 | 110 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 1518 | 0.020 |
Why?
| | Fetal Resorption | 1 | 1994 | 2 | 0.010 |
Why?
| | Pineal Gland | 1 | 1994 | 9 | 0.010 |
Why?
| | Fetal Death | 1 | 1994 | 25 | 0.010 |
Why?
| | Organ Culture Techniques | 1 | 1994 | 44 | 0.010 |
Why?
| | Organ Size | 1 | 1994 | 229 | 0.010 |
Why?
| | Fetus | 1 | 1994 | 195 | 0.010 |
Why?
| | Phlebography | 2 | 1992 | 55 | 0.010 |
Why?
| | Pregnancy | 1 | 1994 | 2658 | 0.010 |
Why?
| | Prothrombin Time | 1 | 1992 | 18 | 0.010 |
Why?
| | Drug Monitoring | 1 | 1992 | 82 | 0.010 |
Why?
| | Warfarin | 1 | 1992 | 82 | 0.010 |
Why?
| | Urogenital System | 1 | 1990 | 4 | 0.010 |
Why?
| | Multiple Trauma | 1 | 1990 | 31 | 0.010 |
Why?
| | Femoral Neck Fractures | 1 | 1990 | 7 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1990 | 162 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1992 | 634 | 0.000 |
Why?
| | Prevalence | 1 | 1990 | 1013 | 0.000 |
Why?
|
|
Barnes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
|